The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML
Clinical trial NCT02204644 · COMPLETED
Trial details
- NCT number
- NCT02204644
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-01
- Primary completion
- 2017-06-01
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.